Clinical Research Strategies has made Life Sciences Review’s annual listing of 10 companies that are at the forefront of providing exemplary services and solutions to obtain Life Science Compliance and, in turn, transform the business bottom line.
We’re proud and honored to receive this prestigious award and to be recognized with Life Sciences Review’s cover story.
CLINICAL RESEARCH STRATEGIES
An End-to-End Approach to Compliance in Life Sciences
Life Sciences Review, March 2021
“In the EU, while regulations are meant for ensuring patients’ safety by adding more conformance requirements, they have severely compromised the Life Sciences industry’s quest to push the boundaries of innovation,” says Alethea Wieland, the President and Founder of Clinical Research Strategies.
According to a study published by Deloitte, “Globalization, alliances and partnerships, heightened transparency expectations, increased emphasis on innovative technologies, and ever-evolving needs for existing and emerging customers are driving them to re-examine their approach to compliance.”
As such, identifying, analyzing, and mitigating compliance risks have evolved into a fundamental prerequisite for Life Sciences companies in developing an effective strategy to help future-proof their business. However, keeping up the innovation pace with this regulatory landscape will no longer be an easy task, especially for startups and mid-sized organizations.
Download the full article as a PDF file.
BRING A WATCHFUL EYE AND SOUND DECISION MAKING TO YOUR BUSINESS
for High Performance and Long-term Sustainability
As your business partner, we don’t push old school clinical trial methods because we aren’t afraid of regulatory reform and empowering you with sound advice about keeping costs and timelines as low as possible, harnessing technology to your benefit, and meeting the regulator’s needs.
